| Quote
: |
蒋云霞,戴小良,陈玲,莫华兰,赵连宇,王航飞.南蛇藤风湿饮治疗类风湿关节炎的时效性研究[J].湖南中医药大学学报英文版,2022,42(12):2022-2028.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 4131times Download 2189times |
| 南蛇藤风湿饮治疗类风湿关节炎的时效性研究 |
| 蒋云霞,戴小良,陈玲,莫华兰,赵连宇,王航飞 |
| (桂林市中医医院风湿病科, 广西 桂林 541002) |
| 摘要: |
| 目的 探讨南蛇藤风湿饮临床治疗类风湿关节炎(rheumatoid arthritis, RA)的作用及时效性。方法 将120例桂林市中医医院收治的RA患者随机平均分为3组,即美洛昔康组、南蛇藤风湿饮组、南蛇藤风湿饮+美洛昔康组,在治疗前、治疗1周后、治疗2周后、治疗3周后对各组临床疾病活动指数(clinical disease activity index, CDAI)、类风湿因子(rheumatoid factor, RF)、抗环瓜氨酸肽(anticyclic citrulline peptide, A-CCP)抗体、C反应蛋白(c-reactive protein, CRP)、红细胞沉降率(erythrocyte sedimentation rate, ESR)、中医证候评分、不良反应率检测及评价。结果 与美洛昔康组相比较,南蛇藤风湿饮组及南蛇藤风湿饮+美洛昔康组在治疗1周后可显著降低CDAI和中医证候评分,在治疗2周后CRP、ESR及治疗总有效率可显著提高,在治疗3周后可显著降低RF及A-CCP(P<0.05)。3组的不良反应率没有明显区别(P>0.05)。结论 南蛇藤风湿饮治疗RA的起效时间较美洛昔康快,临床疗效总体优于美洛昔康,而联合应用南蛇藤风湿饮和美洛昔康对治疗RA具有更为显著的临床疗效,值得在临床中进一步推广与发展。 |
| 关键词: 南蛇藤 美洛昔康 类风湿关节炎 时效性 临床研究 抗风湿药 |
| DOI：10.3969/j.issn.1674-070X.2022.12.011 |
| Received:July 18, 2022 |
| 基金项目:广西壮族自治区中医药管理局项目(GZZC2020299); 第五批全国中医临床优秀人才研修项目(国中医药人教函[2022] 1号) |
|
| The timeliness of Nansheteng Rheumatism Drink in treating rheumatoid arthritis |
| JIANG Yunxia,DAI Xiaoliang,CHEN Ling,MO Hualan,ZHAO Lianyu,WANG Hangfei |
| (Department of Rheumatology, Guilin Hospital of Chinese Medicine, Guilin, Guangxi 541002, China) |
| Abstract: |
| Objective To discuss the effects and timeliness of the Nansheteng Rheumatism Drink in treating rheumatoid arthritis(RA).Methods A total of 120 RA patients were randomly divided into three groups, Meloxicam group, Nansheteng Rheumatism Drink group, Nansheteng Rheumatism Drink + Meloxicam group. Before treatment, 1 week after treatment, 2 weeks after treatment, and 3 weeks after treatment, the clinical disease activity index(CDAI), rheumatoid factor(RF), anticyclic citrulline peptide(A-CCP), c-reactive protein(CRP), erythrocyte sedimentation rate(ESR), TCM syndrome scores and adverse reaction rate were tested and evaluated.Results Compared with Meloxicam group, Nansheteng Rheumatism Drink group and Nansheteng Rheumatism Drink + Meloxicam group can significantly reduce CDAI and TCM syndrome scores after 1 week of treatment, significantly improve CRP, ESR and the total effective rate of treatment after 2 weeks of treatment, and significantly reduce RF and A-CCP after 3weeks of treatment(P<0.05). There was no significant difference in the rate of adverse reactions among the three groups(P>0.05).Conclusion The onset time of Nansheteng Rheumatism Drink in the treatment of RA disease is shorter than that of Meloxicam group, and the overall clinical efficacy is better than that of Meloxicam group. The combined application of Nansheteng Rheumatism Drink and Meloxicam has a more significant clinical efficacy in the treatment of RA, which is worthy of further promotion and development in clinical practice. |
| Key words: Nansheteng(Celastrus Orbiculatus) meloxicam rheumatoid arthritis timeliness clinical study Chinese medicine of anti-rheumatoid arthritis |
|
二维码（扫一下试试看！） |
|
|
|
|
